Source: Annual Congress 2013 –Asthma: new mechanisms and markers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. P. Ligeiro de Oliveira, V. da Silva, M. de Oliveira, Jr., R. Vieira, F. Aimbire (Sao Paulo, Brazil). Low power laser (LBP) therapy downregulates the allergic lung inflammation in experimental asthma model: Effect driven to signal transducer and activator of transduction 6 (STAT-6). Eur Respir J 2013; 42: Suppl. 57, 577

Member's Comments

No comment yet.

Related content which might interest you: Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases Source: International Congress 2015 – Translational studies in airway cell biology Year: 2015 Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Selective decoy-mediated inhibition of activator protein-1 activity in the airways prevents experimental asthmatic inflammation Source: Annual Congress 2005 - Regulation of the allergic and asthmatic response Year: 2005 Enrichment of the Janus kinase (JAK) activation signature in severe asthma sputum: Correlation with IL-13 expression Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 IL-37 requires IL18Rα and SIGIRR to diminish experimental allergic airway inflammation in mice Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma Source: Eur Respir Rev 2009; 19: 46-54 Year: 2010 Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 IL-13-induced cytokine release and hyperresponsiveness in precision cut lung slices of different species – Characterization of a model potentially suitable for translational research of asthma cellular events Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013 Aerobic exercise reduces asthma phenotype by inhibition of JAK2, SOCS3 and STAT6 in airway epithelium and in peribronchial leukocytes Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases Year: 2016 Aerobic training reverses the inhibition in the expression of glucocorticoid receptors and decreases the Th2 allergic inflammation in asthma model Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013 The homologous IL-17 cytokines A and F differentially regulate allergic asthma in murine models Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Rapamycin protects OVA induced asthma in mice through regulating autophagy Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Synergistic effect of human tubal mesenchymal stem cell (htMSCs) and low level laser (LLL) therapy significantly reduces experimental COPD in mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014